A monoclonal antibody targeting ErbB2 domain III inhibits ErbB2 signaling and suppresses the growth of ErbB2-overexpressing breast tumors

The anti-ErbB2 antibodies trastuzumab and pertuzumab in combination have recently been approved for the treatment of patients with ErbB2-positive metastatic breast cancer. Pertuzumab, which binds to ErbB2 near the center of domain II, and trastuzumab, which binds to the juxtamembrane region of ErbB2...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncogenesis
Auteurs principaux: Meng, Y, Zheng, L, Yang, Y, Wang, H, Dong, J, Wang, C, Zhang, Y, Yu, X, Wang, L, Xia, T, Zhang, D, Guo, Y, Li, B
Format: Artigo
Langue:Inglês
Publié: Nature Publishing Group 2016
Sujets:
Original Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4815051/
https://ncbi.nlm.nih.gov/pubmed/26999718
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/oncsis.2016.25
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires